Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
Journal of Psychedelic Studies June 9, 2022 Annie M. Mccartney, H. T. Mcgovern, Alexander de Foe 8 citations
Psychedelic substances like psilocybin and ketamine show promise as antidepressants due to rapid and lasting effects on mood and cognition. Most research focuses on psychiatric settings, but this review argues for a broader biopsychosocial perspective that includes social and psychological factors. Evaluating six major clinical trials, the authors conclude that combining psychedelic treatment with psychotherapy produces more enduring and profound antidepressant effects than either drug alone. This finding encourages people who might self-medicate with psychedelics to seek professional psychological support, reducing risks from unregulated use.